Short report: Idiopathic thrombocytopenic purpura and MMR vaccine
2001/03/01 by Elizabeth Miller, E Miller · 26 citations
Medicine · #Platelet Disorders and Treatments #Blood groups and transfusion #Heparin-Induced Thrombocytopenia and Thrombosis
paper · pdf · doi:10.1136/adc.84.3.227
Abstract
A CAUSAL ASSOCIATION BETWEEN MEASLES: mumps-rubella (MMR) vaccine and idiopathic thrombocytopenic purpura (ITP) was confirmed using immunisation/hospital admission record linkage. The absolute risk within six weeks of immunisation was 1 in 22 300 doses, with two of every three cases occurring in the six week post-immunisation period being caused by MMR. Children with ITP before MMR had no vaccine associated recurrences.
Cited by
- The Role and Safety of Aluminum Adjuvants in Childhood Vaccines
- The average cost of measles cases and adverse events following vaccination in industrialised countries. [europepmc]
- MMR vaccine and idiopathic thrombocytopaenic purpura. [europepmc]
- Pathobiology of secondary immune thrombocytopenia. [europepmc]
- Vaccines for measles, mumps and rubella in children. [europepmc]
- Vaccine administration and the development of immune thrombocytopenic purpura in children. [europepmc]
- Safety assessment of adjuvanted vaccines: Methodological considerations. [europepmc]
- Adverse events of vaccines and the consequences of non-vaccination: a critical review. [europepmc]
- Do Vaccines Trigger Neurological Diseases? Epidemiological Evaluation of Vaccination and Neurological Diseases Using Examples of Multiple Sclerosis, Guillain-Barré Syndrome and Narcolepsy. [europepmc]
- Updated international consensus report on the investigation and management of primary immune thrombocytopenia. [europepmc]
- The Use of Analgesics during Vaccination with a Live Attenuated Yersinia pestis Vaccine Alters the Resulting Immune Response in Mice. [europepmc]
- Immune thrombocytopenic purpura risk by live, inactivated and simultaneous vaccinations among Japanese adults, children and infants: a matched case-control study. [europepmc]
- Vaccines for measles, mumps, rubella, and varicella in children. [europepmc]
- The Practice Guideline for Vaccinating Korean Patients with Autoimmune Inflammatory Rheumatic Disease. [europepmc]
- Severe Immune Thrombocytopenia Following MMR Vaccination with Rapid Recovery: A Case Report and Review of Literature. [europepmc]
- Severe, Refractory Immune Thrombocytopenia Occurring After SARS-CoV-2 Vaccine. [europepmc]
- Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS). [europepmc]
- COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement. [europepmc]
- COVID-19 vaccination associated severe immune thrombocytopenia. [europepmc]
- Vaccinations and Autoimmune Diseases. [europepmc]
- Immune thrombocytopenia in 2 healthy young women after the Pfizer-BioNTech BNT16B2b2 messenger RNA coronavirus disease 2019 vaccination. [europepmc]
- Immune thrombocytopenia following immunisation with Vaxzevria ChadOx1-S (AstraZeneca) vaccine, Victoria, Australia. [europepmc]
- Vaccines for measles, mumps, rubella, and varicella in children. [europepmc]
- Immune Thrombocytopenia Induced by the Chimpanzee Adenovirus-Vectored Vaccine against SARS-CoV-2 Infection. [europepmc]
- Current Approaches to Vaccine Safety Using Observational Data: A Rationale for the EUMAEUS (Evaluating Use of Methods for Adverse Events Under Surveillance-for Vaccines) Study Design. [europepmc]
- Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinations. [europepmc]
Related